Human Health
Synthetic Lethality – Targeting FEN1 for more selective cancer therapy
CDR007- Project Leaders: Philip Hieter
- Institutions: University of British Columbia (UBC)
- Budget: $495000
- Program/Competition: Other Programs
- Genome Centre(s): Genome British Columbia
- Status: Closed
This project proposes to screen additional CDRD chemical libraries in order to identify a greater number of unique compounds that inhibit FEN1 at low micromolar potency. In parallel, a complimentary medicinal chemistry program will be established around both the current inhibitors identified and inhibitors to be identified in the above screens in order to generate new IP on a series of pharmacophores. Future work will assess hits for toxicity and pharmacokinetic parameters and evaluate activity in cancer xenograft models.
Outcomes:
The project has ended successfully with 11 active compounds identified in in-vivo model. A 4th iteration is on-going.
